EQUITY RESEARCH MEMO
Oncodesign Services
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)65/100
Oncodesign Services is a French contract research organization (CRO) founded in 1995, specializing in integrated drug discovery and preclinical services for oncology, inflammation, and infectious diseases. The company leverages AI and machine learning to enhance target identification and drug development, and operates a proprietary radiochemistry and bioconjugation platform. With a comprehensive suite spanning from target identification to IND filing support, Oncodesign Services serves a global client base seeking efficient and innovative preclinical solutions. The company is privately held and pre-clinical stage, positioning itself as a technology-enabled CRO with a focus on complex therapeutic areas.
Upcoming Catalysts (preview)
- Q3 2026Announcement of new AI-driven drug discovery partnership70% success
- Q4 2026Expansion of radiochemistry platform capabilities60% success
- TBDRelease of case studies highlighting AI-enabled success in oncology75% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)